Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00516386 · ClinicalTrials.gov registry record · Phase 1

Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents

A Phase 1 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT00516386: Completed Phase 1 study, sponsored by Massachusetts General Hospital.

NCT00516386 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00516386, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.

Interventions

  • DRUG RhIGF-1

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2007-03
Est. Completion 2008-12
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What the finished NCT00516386 record still lists

NCT00516386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 1 intervention - of which RhIGF-1 is the first listed.

NCT00516386 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00516386 about?

NCT00516386 is a clinical study titled "Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents". The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.

What is the current status of trial NCT00516386?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-03. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00516386?

The interventions under investigation include: RhIGF-1 (DRUG).

Who is sponsoring clinical trial NCT00516386?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00516386's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00516386, the US trial registry maintained by the National Library of Medicine. NCT00516386 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.